Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions
Source: SeekingAlpha
2025-02-13 23:45:44 ET
More on Bio-Rad Labs, Bio-Rad Laboratories, Inc., etc.
- Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
- Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential
- Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
- Bio-Rad Labs Non-GAAP EPS of $2.90 beats by $0.02, revenue of $667.5M misses by $12.25M
- Bio-Rad Labs Q4 2024 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
1.56% G/L:
$281.74 Last:
236,389 Volume:
$281.82 Open:
BIO Latest News
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
